



Sanofi, DAP & LGS Partner to Fight Diabetes in School Children

KiDS (Kids and Diabetes in Schools) project aims to foster a school environment that creates a better understanding of diabetes and support children with this condition.

Karachi, Pakistan – November 10, 2016 – Sanofi-aventis Pakistan limited (Sanofi Pakistan), Diabetic Association of Pakistan (DAP) and Lahore Grammar School (LGS) announced the successful kick-off of the KiDS & Diabetes in Schools Project in Pakistan.

KiDS is an international collaborative project of the International Diabetes Federation (IDF) and multiple partners, including Sanofi. The KiDS project aims to foster a safe and supportive school environment for children with diabetes to manage their condition and prevent discrimination while raising awareness about diabetes and the benefits of healthy eating habits and physical activity among school-age children. Following Brazil and India, Pakistan is the 3rd country to launch this project.

“KiDS is an educational project which disseminates information on diabetes and how it can be prevented and managed. The program is primarily developed for school children, school staff, parents of children with diabetes and parents in general. Sanofi is a world leader in diabetes care, offering solutions and support to patients to assist them throughout their journey with this lifelong condition” said Asim Jamal, Country Chair and Managing Director, Sanofi Pakistan, elaborating on the dynamics of the project.

Pakistan has approximately 1.6 million children with Type-1 Diabetes. Undetected Type-1 diabetes could pose a serious challenge for children and families, who need adequate knowledge and resources for effective management of the condition.

Lahore’s leading Diabetes Specialist, Dr. Fauzia Moyeen conducted the inaugural program at the Main Gulberg branch of LGS. She presented information on healthy eating habits and the importance of exercise to children through an engaging interactive classroom session while with teachers her focus was more on the identification of early signs and symptoms of diabetes.

The Principal of Lahore Grammar School, Nasrene Shah, said: *“Lahore Grammar School is privileged to be the very first school in the country to partner Sanofi and DAP for the KiDS program. Having participated in the KiDS workshop, our teaching staff is now better equipped to play a very positive role in the classroom with children who may be showing signs and symptoms of Type 1 diabetes or coping with this condition already”*.

Emphasizing the importance of diet and an active lifestyle, Prof. A. Samad Shera (Secretary General of the Diabetic Association of Pakistan, Honorary President International Diabetes Federation, Head of WHO Collaborating Center) said: *“The twin epidemics of the 21st century, Diabetes and Obesity, are becoming common in Pakistan. Children must avoid junk food which I would refer to as weapons of mass destruction. The KiDS program will help protect future generations from diabetes and obesity and their serious complications. I am hopeful that Sanofi and Diabetic Association of Pakistan will partner with more stakeholders for KiDS in future.”*



About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: [SAN](#)) and in New York (NYSE: [SNY](#)).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Name: Laila Khan
Tel. : +9221 35060221-35
Laila.khan@sanofi.com